Penmenvy

News

GSK joins arch-rival Pfizer in the market for five-in-one meningococcal vaccines with FDA approval for Penmenvy, a top launch prospect for 2025.

News

Shares in Tenax 85% of their value after its drug for patients with pulmonary hypertension caused by a form of heart failure flunked a phase 3 trial.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.